Anika's Cingal succeeds in Phase III 19-01, beats steroid alone at 26 weeks

Anika Therapeutics, Inc.

Cingal met primary endpoint in U.S. Phase III study 19-01: superior to TH steroid at 26 weeks (p=0.0406).
Across three Phase III studies (n=741), Cingal showed mean 71% pain improvement and 91% responder rate at 26 weeks.
Anika to meet FDA in coming months to discuss next steps for U.S. regulatory approval of Cingal.
FDA may require a single full factorial pivotal study before NDA submission, as per prior advice.
Cingal already commercialized in over 35 countries; Anika exploring U.S. and Asian commercial partnerships.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.